JP2011507820A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011507820A5 JP2011507820A5 JP2010538906A JP2010538906A JP2011507820A5 JP 2011507820 A5 JP2011507820 A5 JP 2011507820A5 JP 2010538906 A JP2010538906 A JP 2010538906A JP 2010538906 A JP2010538906 A JP 2010538906A JP 2011507820 A5 JP2011507820 A5 JP 2011507820A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- derivative
- vitamin
- agent
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 150000003712 vitamin E derivatives Chemical class 0.000 claims description 16
- 230000030833 cell death Effects 0.000 claims description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 239000003550 marker Substances 0.000 claims description 8
- 229930003799 tocopherol Natural products 0.000 claims description 8
- 229960001295 tocopherol Drugs 0.000 claims description 8
- 239000011732 tocopherol Substances 0.000 claims description 8
- 235000010384 tocopherol Nutrition 0.000 claims description 8
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims description 6
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 claims description 5
- 102000000412 Annexin Human genes 0.000 claims description 4
- 108050008874 Annexin Proteins 0.000 claims description 4
- 210000001525 retina Anatomy 0.000 claims description 4
- 125000002640 tocopherol group Chemical group 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 102000004121 Annexin A5 Human genes 0.000 claims description 2
- 108090000672 Annexin A5 Proteins 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- -1 D-α-tocopheryl succinate ester Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 7
- 210000003488 posterior eye segment Anatomy 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0724772.9 | 2007-12-19 | ||
| GBGB0724772.9A GB0724772D0 (en) | 2007-12-19 | 2007-12-19 | Carrier |
| PCT/GB2008/004233 WO2009077769A2 (en) | 2007-12-19 | 2008-12-19 | Carrier |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011507820A JP2011507820A (ja) | 2011-03-10 |
| JP2011507820A5 true JP2011507820A5 (https=) | 2012-02-02 |
| JP5584136B2 JP5584136B2 (ja) | 2014-09-03 |
Family
ID=39048371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010538906A Expired - Fee Related JP5584136B2 (ja) | 2007-12-19 | 2008-12-19 | 担体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9539203B2 (https=) |
| EP (1) | EP2234596B1 (https=) |
| JP (1) | JP5584136B2 (https=) |
| CN (1) | CN102083411B (https=) |
| CA (1) | CA2709259C (https=) |
| ES (1) | ES2612347T3 (https=) |
| GB (1) | GB0724772D0 (https=) |
| WO (1) | WO2009077769A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0905348D0 (en) | 2009-03-27 | 2009-05-13 | Ucl Business Plc | Carrier |
| IL282113B2 (en) * | 2018-11-21 | 2024-11-01 | Knauf Gips Kg | Use of co2 as water demand reducer in gypsum stucco rehydration mortars |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198432A (en) * | 1988-01-29 | 1993-03-30 | Center For Innovative Technology | Method of preventing chlorohydrocarbon toxicity using sterol derivatives |
| EP0708646A1 (en) * | 1994-05-06 | 1996-05-01 | Alcon Laboratories, Inc. | Use of vitamin e tocopheryl derivatives in ophthalmic compositions |
| WO2003090682A2 (en) * | 2002-04-25 | 2003-11-06 | The Scripps Research Institute | Treatment and prevention of pulmonary conditions |
| ITRM20030153A1 (it) * | 2003-04-03 | 2004-10-04 | Exall S R L | Formulazione idrosolubile contenente ubichinone per uso oftalmico. |
| WO2007112403A2 (en) * | 2006-03-27 | 2007-10-04 | The Regents Of The University Of Colorado | Prevention and treatment of ischemia-reperfusion injury |
-
2007
- 2007-12-19 GB GBGB0724772.9A patent/GB0724772D0/en not_active Ceased
-
2008
- 2008-12-19 ES ES08862245.1T patent/ES2612347T3/es active Active
- 2008-12-19 CN CN200880121274.9A patent/CN102083411B/zh not_active Expired - Fee Related
- 2008-12-19 EP EP08862245.1A patent/EP2234596B1/en not_active Not-in-force
- 2008-12-19 WO PCT/GB2008/004233 patent/WO2009077769A2/en not_active Ceased
- 2008-12-19 US US12/809,262 patent/US9539203B2/en not_active Expired - Fee Related
- 2008-12-19 JP JP2010538906A patent/JP5584136B2/ja not_active Expired - Fee Related
- 2008-12-19 CA CA2709259A patent/CA2709259C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073123A1 (es) | Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica | |
| ES3041835T3 (en) | Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition | |
| AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
| BR0302584A (pt) | Combinação de brimonidina e timolol para uso oftálmico tópico | |
| PH12013500923A1 (en) | Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative | |
| NZ581589A (en) | Solubilized sterile injectable formulation of docetaxel without Tween 80 | |
| MX2021013582A (es) | Composiciones que comprenden agentes biologicamente activos y sales biliares. | |
| WO2012032360A3 (en) | Novel use | |
| JP2012525399A5 (https=) | ||
| BR112012030653A2 (pt) | composição tópica em aerosol, estável ao armazenamento e substancialmente anidra, e, recipiente pressurizado | |
| CO6650415A2 (es) | Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa | |
| NZ711179A (en) | Oral formulations of deferasirox | |
| Nardi et al. | Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery | |
| JP2007515423A5 (https=) | ||
| WO2008116890A3 (en) | Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders | |
| BRPI0806863B8 (pt) | uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv | |
| MX345042B (es) | Composiciones y métodos para tratamiento no quirúrgico de ptosis. | |
| CA2692191C (en) | Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases | |
| JP2012520882A5 (https=) | ||
| BR112014016661A2 (pt) | formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma | |
| WO2009022897A3 (es) | Composición farmacéutica sinergica, útil para inhibir la neovascularización (angiogénesis) corneal y retinal y de otros órganos en un humano o animal | |
| JP2013518051A5 (https=) | ||
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| CL2009001267A1 (es) | Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis. | |
| AR065816A1 (es) | Regimen anticonceptivo oral |